umifenovir has been researched along with chloroquine in 21 studies
| Studies (umifenovir) | Trials (umifenovir) | Recent Studies (post-2010) (umifenovir) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
|---|---|---|---|---|---|
| 234 | 23 | 172 | 16,405 | 763 | 4,029 |
| Protein | Taxonomy | umifenovir (IC50) | chloroquine (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
| Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
| Procathepsin L | Homo sapiens (human) | 5.47 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
| Beta-secretase 1 | Homo sapiens (human) | 7 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 20 (95.24) | 2.80 |
| Authors | Studies |
|---|---|
| Keller, PA; Mahalingam, S; Rashad, AA | 1 |
| Dong, L; Gao, J; Hu, S | 1 |
| Wang, Y; Zhu, LQ | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Amore, A; Bimonte, S; Cascella, M; Celentano, E; Crispo, A; Cuomo, A | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| Cai, C; Deng, Y; Hu, ZY; Huang, K; Huang, Y; Wang, X; Wang, Y; Xie, J; Xie, Y; Xu, D; Zang, J; Zhan, T; Zheng, F | 1 |
| Cai, W; Cao, Y; Chen, X; Hu, F; Li, F; Li, L; Li, Y; Lin, W; Ou, X; Tang, X; Wen, C; Xie, Z | 1 |
| Brun, P; Dubois, J; Dulière, V; Julien, T; Lina, B; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Terrier, O; Traversier, A | 1 |
| Guo, F; Li, S; Liu, C; Shang, D; Taleb, SJ; Tong, M | 1 |
| Mishra, SK; Tripathi, T | 1 |
| Chen, X; Huang, Z; Kuang, Y; Liu, C; Liu, P; Pan, P; Yin, M | 1 |
| Kumar, D; Trivedi, N; Verma, A | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Cai, L; Cao, Y; Fu, M; Guo, X; Hong, L; Yi, G; Ying, P; Zhang, Y | 1 |
| Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M | 1 |
| He, J; Li, C; Li, M; Wang, Y; Yang, Y; Yi, Y; Yu, T; Zhao, K; Zhu, J | 1 |
| Bao, Y; Chen, Z; Ding, J; Feng, Y; Guan, H; Li, H; Liu, W; Wang, X; Zhou, Z | 1 |
11 review(s) available for umifenovir and chloroquine
| Article | Year |
|---|---|
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus Infections; COVID-19; Female; Humans; Indoles; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Male; Pandemics; Pharmaceutical Services; Pneumonia, Viral; Practice Guidelines as Topic; Prognosis; Ribavirin; Risk Assessment; Severe Acute Respiratory Syndrome; Treatment Outcome | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Lopinavir; Multicenter Studies as Topic; Neuraminidase; Pandemics; Pneumonia, Viral; Primates; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
Traditional Chinese Medicine as Potential Therapy for COVID-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Janus Kinase Inhibitors; Lopinavir; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses | 2021 |
Possible treatment and strategies for COVID-19: review and assessment.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles | 2020 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate | 2021 |
1 trial(s) available for umifenovir and chloroquine
| Article | Year |
|---|---|
Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Case-Control Studies; China; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Indoles; Interleukin-17; Lopinavir; Middle Aged; Ribavirin; Ritonavir; Safety; SARS-CoV-2; Th17 Cells; Treatment Outcome | 2020 |
9 other study(ies) available for umifenovir and chloroquine
| Article | Year |
|---|---|
Chikungunya virus: emerging targets and new opportunities for medicinal chemistry.
Topics: Alphavirus Infections; Chikungunya Fever; Chikungunya virus; Disease Outbreaks; Europe; Humans; Models, Molecular | 2014 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Studies as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Discovery; Humans; Indoles; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleotides; SARS-CoV-2; Virus Replication | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Treatment strategies of hospitalized patients with coronavirus disease-19.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Female; gamma-Globulins; Glucocorticoids; Hospitalization; Humans; Immunologic Factors; Indoles; Interferons; Lopinavir; Male; Middle Aged; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019.
Topics: Adult; Anal Canal; Antiviral Agents; C-Reactive Protein; Chloroquine; COVID-19; COVID-19 Testing; Female; Hospitalization; Humans; Indoles; Intensive Care Units; Lymphopenia; Male; Middle Aged; Oseltamivir; Pharynx; Retrospective Studies; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Viral Load | 2021 |
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Berberine; Betacoronavirus; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cyclosporine; Drug Antagonism; Drug Combinations; Drug Repositioning; Drug Synergism; Humans; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vero Cells | 2020 |
Determining available strategies for prevention and therapy: Exploring COVID‑19 from the perspective of ACE2 (Review).
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Cardiovascular Diseases; Chloroquine; COVID-19; Host-Pathogen Interactions; Humans; Indoles; Molecular Targeted Therapy; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Internalization | 2021 |
Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19.
Topics: Antiviral Agents; China; Chloroquine; COVID-19 Drug Treatment; Humans; Indoles; Length of Stay; Retrospective Studies | 2021 |
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Drugs, Chinese Herbal; Electrocardiography; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Indoles; Interferons; Long QT Syndrome; Lopinavir; Male; Middle Aged; Odds Ratio; Quinolones; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index | 2021 |